New drug combo for advanced stomach cancer with CLDN18.2
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer, gastroesophageal junction cancer, or esophageal cancer that has not been treated before.
- Your tumor must test positive for a protein called Claudin18.2 (CLDN18.2).
- Your tumor must also be tested for PD-L1 (a protein that tells if you might benefit from immunotherapy).
- You must be in good physical condition (ECOG 0 or 1), meaning you can carry out daily activities with little or no help.
- Your cancer must not be HER2-positive (a different type of protein).
- You must be at least 18 years old and weigh at least 35 kg (about 77 lbs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (ONO-4578) combined with the usual immunotherapy (nivolumab) and chemotherapy for stomach cancer that has not been treated before. It aims to see if adding this drug helps shrink tumors or slows disease growth better than placebo.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This Phase 2 study tests new combination treatments for advanced stomach or stomach-esophagus junction cancer that cannot be removed by surgery. It may help people whose tumors are positive for a marker called Claudin18.2, which the study uses to choose who can receive the treatment.
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.